Foundation Venture Capital Group President Honored by New Jersey Technology Council
NEW BRUNSWICK, N.J., June 10, 2011 /PRNewswire-USNewswire/ -- James M. Golubieski, president of New Brunswick-based Foundation Venture Capital Group, LLC, has been honored as a Financier of the Year by the New Jersey Technology Council.
The award is presented to a venture capitalist, investment merchant or commercial banker who has contributed to the economic development of New Jersey's technology community.
Foundation Venture Capital Group (FVCG), established in 2006 with funding from its parent company, New Jersey Health Foundation, invests in technology companies formed by researchers at the University of Medicine and Dentistry of New Jersey.
"The mission of FVCG allows us to strengthen the biotech industry in our state as we support groundbreaking research being conducted at the University. We are delighted that Jim has been recognized for his hard work in helping to advance New Jersey's technology community, which is so important to the long-term success of our state," noted Roger S. Fine, chair of the New Jersey Health and Foundation Venture Capital Group Boards of Directors.
Since inception, Foundation Venture Capital Group has invested in six companies, committing up to $500,000 to each one:
- Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies;
- CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
- Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
- Durin Technologies, working to develop a blood test to diagnoses Alzheimer's disease
- Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was recently sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
- Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.
For more information about Foundation Venture Capital Group, contact Jim Golubieski at (908) 731-6601, [email protected] or visit www.foundationventure.com.
SOURCE Foundation Venture Capital Group, LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article